Decheng Capital (investor - Venture Capital)

See something wrong or missing? Let us know
Offices:California

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence.

Average round investment:50M USD
Average number per year:1.0
Distribution: 2026 (1)2020 (1)
Portfolio companies: Switzerland Polares medical
Mostly invests in: Switzerland Switzerland (2) Biotech (2)

2 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Decheng Capital

Name Criteria
United States Acorn Bioventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Supermoon Capitals
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Pivotal bioVenture Partners
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Abingworth
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States 5AM Ventures
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Concord Health Partners
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Fresenius Medical Care Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top